EUVIMEDObjevte EUVIMED
FallberichtOpen access · CC BY-NC 4.0

Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: A case series and clinical guide

Andrew Willeford iD, Jorge Silva Enciso iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023-12 · 43 (12) · 1397-1404

DOI: 10.1002/phar.2874 ↗

At a glance

Fallbericht in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, published online on 2023-09-15. Written by Andrew Willeford and 1 co-authors. Institution: UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, California, USA. Major MEDLINE topics: Disopyramide, Cardiomyopathy, Hypertrophic. Cited 13 times so far (Crossref); 10 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background

Hypertrophic cardiomyopathy (HCM) is a genetic disorder for which first‐line treatments for obstructive HCM (oHCM) include beta‐blockers, non‐dihydropyridine calcium channel blockers, and disopyramide for refractory cases. Mavacamten, a selective cardiac myosin inhibitor, is indicated for symptomatic oHCM to improve functional capacity and symptoms. Use of disopyramide and mavacamten together is not recommended due to concerns of additive negative inotropic effects. Transitioning from disopyramide to mavacamten may be preferred to avoid adverse effects and frequent administration, however, the best approach for making the transition has not been established. Cases We present a series of seven patients with oHCM who transitioned from disopyramide to mavacamten and underwent echocardiograms mandated by a Risk Evaluation and Mitigations Strategies program. Two methods were employed. The first approach, involving washout of disopyramide before starting mavacamten, resulted in worsening of heart failure symptoms in the first two cases. The second approach, involving tapering disopyramide when starting mavacamten, was successfully implemented in the last five cases, with no adverse effects or worsening of systolic dysfunction.

Conclusion

Our method of tapering disopyramide when starting mavacamten using a stepwise approach is feasible and safe. Our report fulfills an unmet need by serving as a guide for other clinicians who seek to transition their patients from disopyramide to mavacamten.

Subjects

MeSH terms (MEDLINE)

DisopyramideCardiomyopathy, HypertrophicHumansBenzylaminesAdrenergic beta-AntagonistsUracil

Author keywords

disopyramidehypertrophic cardiomyopathymavacamten

Substances

DisopyramideBenzylaminesAdrenergic beta-AntagonistsMYK-461Uracil

Authors and institutions

  • UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, California, USA.
  • Division of Cardiology, Department of Medicine, University of California San Diego, San Diego, California, USA.

ORCID profiles: Andrew Willeford, Jorge Silva Enciso

Cite

APA

Willeford, A., & Silva Enciso, J. (2023). Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: A case series and clinical guide. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 43(12), 1397-1404. https://doi.org/10.1002/phar.2874

Vancouver

Willeford A, Silva Enciso J. Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: A case series and clinical guide. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023;43(12):1397-1404. doi:10.1002/phar.2874

BibTeX
@article{Willeford2023,
  author = {Willeford, Andrew and Silva Enciso, Jorge},
  title = {Transitioning disopyramide to mavacamten in obstructive hypertrophic cardiomyopathy: A case series and clinical guide},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2023},
  volume = {43},
  number = {12},
  pages = {1397--1404},
  doi = {10.1002/phar.2874}
}
Start for free →